

Section S: Blood Product Overview –
PRIVIGEN® Immune Globulin Intravenous (IVIG) 10%
CSL Behring Page
1 of 3

| | |
|-----------------------------------------------------------------------|---|
| DESCRIPTION of PRODUCT | 1 |
| AVAILABILITY of PRODUCT | 1 |
| STORAGE of PRODUCT | 2 |
| CLINICAL INDICATIONS (see package insert for contraindications) | 2 |
| REQUESTS for PRIVIGEN..... | 2 |
| ADMINISTRATION of PRODUCT | 3 |
| ADDITIONAL COMMENTS | 3 |
| LINK to WEBSITE for PRESCRIBING INFORMATION | 3 |

DESCRIPTION of PRODUCT

- Privigen® is manufactured from large pools of human plasma by a combination of cold alcohol fractionation, octanoic acid fractionation and anion exchange chromatography.
- Viral reduction steps include octanoic acid fractionation, pH 4 incubation, virus filtration.
- Privigen® contains approximately 100mg of human immunoglobulin per mL, with a purity of at least 98% IgG.
- pH is 4.8
- Stabilizing agent is L-Proline with no preservative.
- Contains on average 2.7µg/mL IgA.
- **Baxter Gammagard S/D® contains the least amount of IgA of all the IVIG products manufactured, and should be the product that is used, with caution, if a patient that has an anti-IgA requires IVIG. This product is not routinely stocked, and will be ordered only if a patient has a documented anti-IgA.**

AVAILABILITY of PRODUCT

- The CBS provides 3 different IVIG products from 3 different manufacturers, and requires all hospitals to use Talecris [Gamunex](#) (or CBS IGIV-nex), Baxter [Gammagard](#) Liquid and CSL Behring Privigen at a predetermined percentage.
- All LHSC/SJHC sites stock IVIG. Contact the BTL to see which specific product(s) is stocked at your site.

Date effective: Jan 2009

Date revised: Oct 2009

Section S: Blood Product Overview – PRIVIGEN[®] Immune Globulin Intravenous (IVIG) 10% CSL Behring

Page
2 of 3

- Patient should NOT receive IVIG products from different manufacturers in the same dose.
- All attempts will be made to maintain a patient on the same product throughout their course of treatment, but in some circumstances it may be necessary to substitute.

STORAGE of PRODUCT

- CSL Behring Privigen[®] can be stored at Room Temperature (up to 25°C).
- Do NOT freeze.
- Expiry date is on each vial. Once entered the vial should be infused within 4 hours.

CLINICAL INDICATIONS (see package insert for contraindications)

- Primary humoral immune deficiency;
- Kawasaki's disease;
- Pediatric post-liver or -BMT transplant;
- Pediatric sepsis;
- Hemolytic Disease of the Newborn;
- Prophylaxis of alloimmune neonatal thrombocytopenia;
- Idiopathic Thrombocytopenia Purpura;
- Necrotizing fasciitis ("flesh eating" disease);
- Prophylaxis of allogenic bone marrow transplant recipients;
- Prophylaxis of infection in BMT;
- Autoimmune neutropenia with severe bacterial infections;
- Neurological disorders (Guillain-Barre, myasthenia gravis);
- Renal transplant rejection.

REQUESTS for PRIVIGEN

- "IVIG Request Form" must be completed when IVIG is initially requested for patient.
- Any request for use other than above indications requires pre-authorization by a Hematologist. If product is in short supply, each request is assessed on a case-by case basis, and IVIG is issued based on diagnosis and product availability.
- Maximum volume issued for a patient at any given time: 24 hour dose.

Date effective: Jan 2009

Date revised: Oct 2009

Section S: Blood Product Overview – PRIVIGEN[®] Immune Globulin Intravenous (IVIG) 10% CSL Behring

Page
3 of 3

ADMINISTRATION of PRODUCT

- Should be inspected visually for particulate matter and discolouration prior to administration. Infuse only if solution is colourless, free of particulate matter and not turbid.
- IVIG should only be administered intravenously.
- IVIG is issued from the BTL in a glass bottle and requires a vented administration set. Vented administration sets for use with Infusion Pumps can be obtained from HMMS (#38680). Do NOT use a needle as a vent. *NOTE:* Privigen[®] does not need to be filtered.
- Dosage is determined by the clinical indication. See product insert.
- Infusions should be started slowly (possible anaphylactic reactions).
- Rates should be specified by ordering physician. Guidelines include an initial rate of 0.01-0.02mL/kg/minute with a gradual increase to 0.06mL/kg/minute if tolerated well.
- Maximum approved rate for Privigen[®] is 0.12mL/kg/min.
- Vital signs should be taken and documented pre-infusion, at each rate increase and at least hourly until infusion is complete.
- IVIG is only compatible with 5% dextrose in water. Do not administer together with 0.9% NaCl.
- If dilution is required, contact the BTL.

ADDITIONAL COMMENTS

- Comparison chart of the different IVIGs available in Canada is provided by the [Canadian Blood Services](#) (Plasma Protein Products Information, Product Comparison Tables, Immune Globulin Comparison Table).
- A Subcutaneous Immune Globulin (SCIg) has been approved for the treatment of Primary Immune Deficiency (PID) and is available as an alternate to IVIG. See CSL Behring [Vivaglobin[®]](#) for additional information.

LINK to WEBSITE for PRESCRIBING INFORMATION

Product monograph available at: http://www.privigen.com/pdf/Privigen_PI.pdf

Date effective: Jan 2009

Date revised: Oct 2009